Spero Therapeutics (SPRO) Capital Expenditures (2016 - 2020)

Spero Therapeutics (SPRO) has reported Capital Expenditures for 5 consecutive years, with $12000.0 the latest figure, recorded in Q4 2020.

• For the quarter ending Q4 2020, Capital Expenditures fell 90.7% year-over-year to $12000.0; the trailing twelve-month figure through Sep 2021 stood at $78000.0 (down 71.53% YoY), and the FY2020 full-year result was $157000.0, down 50.0% from the prior year.
• Capital Expenditures declined to $12000.0 in Q4 2020 per SPRO's latest filing, from $51000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $2.4 million in Q4 2018 and bottomed at -$1000.0 in Q4 2017.
• Historically, Capital Expenditures has averaged $285909.1 across 5 years, with a median of $79000.0 in 2020.
• The sharpest annual moves came in 2017 and 2018: Capital Expenditures tumbled 100.38% in 2017, then soared 241500.0% in 2018.
• Over 5 years, Capital Expenditures stood at $261000.0 in 2016, then sank by 100.38% to -$1000.0 in 2017, then jumped by 241500.0% to $2.4 million in 2018, then slumped by 94.66% to $129000.0 in 2019, then slumped by 90.7% to $12000.0 in 2020.
• According to Business Quant data, Capital Expenditures over the past three periods registered $12000.0, $51000.0, and $15000.0 for Q4 2020, Q3 2020, and Q2 2020 respectively.